A5100398399- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Mesenchymal stem cell research
- Chronic Myeloid Leukemia Treatments
- Polyomavirus and related diseases
- CNS Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Cancer-related molecular mechanisms research
- Platelet Disorders and Treatments
- Nausea and vomiting management
- Hemophilia Treatment and Research
- Retinoids in leukemia and cellular processes
- Renal Transplantation Outcomes and Treatments
- Viral-associated cancers and disorders
- Mycobacterium research and diagnosis
- Pathogenesis and Treatment of Hiccups
- Ferroptosis and cancer prognosis
West China Hospital of Sichuan University
2012-2024
Sichuan University
2012-2024
State Key Laboratory of Biotherapy
2022-2023
Cleveland Clinic Lerner College of Medicine
2019-2022
Shaanxi Provincial People's Hospital
2022
Weatherford College
2021
MicroRNA-142-3p (miR-142-3p) is dysregulated in many malignancies and may function as a tumor suppressor or oncogene tumorigenesis development. However, few studies have investigated the clinical significance biological of miR-142-3p hepatocellular carcinoma (HCC).The expression levels taurine upregulated gene 1 (TUG1), miR-142-3p, zinc finger E-box-binding homeobox (ZEB1) were evaluated HCC tissues cell lines by quantitative real-time PCR. MTT colony formation assays used to detect...
Abstract Multiple myeloma (MM) is an aggressive malignancy characterized by terminally differentiated plasma cells accumulation in the bone marrow (BM). MM BM exhibits elevated MΦs (macrophages) numbers relative to healthy BM. Current evidence indicates that MM-MΦs (MM-associated macrophages) have pro-myeloma functions, and negatively correlate with patient survival. Here, we found BMI1, a polycomb-group protein, modulates functions of MM-MΦs, which expressed higher BMI1 levels normal MΦs....
Previous studies highlight the need for a more active conditioning therapy in high-risk or refractory and relapsed lymphomas. Our preclinical research shows that histone deacetylase inhibitors, such as either vorinostat chidamide, sensitize lymphoma cells to cytotoxic combination of cladribine, gemcitabine busulfan, leading cell apoptosis. To evaluate efficacy this chidamide-cladribine-gemcitabine-busulfan (ChiCGB) new therapy, we conducted Phase II trial, described here. Patients with...
Abstract Multiple myeloma, a plasma cell malignancy in the bone marrow, remains largely incurable with currently available therapeutics. In this study, we discovered that activated leukocyte adhesion molecule (ALCAM) interacted epidermal growth factor receptor (EGFR), and regulated myelomagenesis. ALCAM was negative regulator of myeloma clonogenicity. expression positively correlated patients’ survival. ALCAM-knockdown cells displayed enhanced colony formation presence marrow stromal...
Hemostatic materials are generally applied in surgical operations for cancer, but their effects on the growth and recurrence of tumors unclear. Herein, three commonly used naturally derived hemostatic materials, gelatin sponge, Surgicel (oxidized regenerated cellulose), biopaper (mixture sodium hyaluronate carboxymethyl chitosan), were cocultured with A549 human lung adenocarcinoma cells vitro. Furthermore, performance tumorigenicity cells observed after subcutaneous implantation into...
Background: Bloodstream infection (BSI) is a serious medical issue causing non-relapsed mortality in patients receiving hematopoietic stem cell transplantations (HSCT). Methods: The characteristics of all HSCT (autologous and allogeneic HSCT) our hospital from 2013 to 2019 were studied. Ratios, medians, ranges calculated describe categorical variables. Chi-square tests performed compare the difference between ratios. Results: A total 741 746 procedures—including 376 allogeneic, 370...
Chromosomal aberrations are generally considered to have a remarkable impact on the outcome of multiple myeloma. Bortezomib helps achieve complete responses and leads longer life expectancy in many myeloma patients. This study was designed clarify whether bortezomib can improve poor prognosis resulting from del(17q13), del(13q14), amp(1q21), t(4,14), t(14,16) patients with A total 255 MM treated bortezomib-based regimens were included this study. All chromosomal detected by interphase...
The prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic lymphoma (T-LBL) remains poor under current conditioning regimens before receiving autologous stem cell transplantation (ASCT).Patients PTCL T-LBL were enrolled to receive ASCT using the regimen chidamide, cladribine, gemcitabine, and busulfan (ChiCGB). Positron emission tomography-computed tomography (PET/CT) was used evaluate response ASCT. Overall survival (OS) progression-free (PFS) employed assess patient outcome,...
Acute graft versus host disease (aGvHD) is a severe complication that arises in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and remains the primary cause of nonrelapse mortality (NRM). The MAGIC algorithm probability (MAP) has been proposed to identify at intermediate high risk developing aGvHD. levels suppression tumorigenicity 2 (ST2) regenerating islet-derived 3α (Reg3α) were assessed, MAP was calculated on days 7, 14, 21, 28 after allo-HSCT. Based...
Abstract Background Mesenchymal stem cells (MSCs) are a class of adult with self-renewal and multidirectional differentiation potential that may be treatment for aplastic anemia (AA). Method Umbilical cord-derived MSCs were cultured in three media (Mesencult-XF, MCL, StemPro MSC SFM CTS). HGF, PGE2, ANG-1, TGF-β1, IFN-γ, TNF-α detected using ELISA. The AA mouse model was built via post-irradiation lymphocyte infusion. After different treatments, routine blood, VEGF, Tregs every week. On day...